-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EILjoFpBox5RkN273++AOO/vbnH5EDNA3YeXdEgIV/124jRHlmzzH8zgUcX7pAq9 z1Oz8bz0IJsE22vfeMglzQ== 0001254318-03-000005.txt : 20031014 0001254318-03-000005.hdr.sgml : 20031013 20031014170318 ACCESSION NUMBER: 0001254318-03-000005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20031010 FILED AS OF DATE: 20031014 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GARNICK ROBERT L CENTRAL INDEX KEY: 0001214124 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09813 FILM NUMBER: 03940167 MAIL ADDRESS: STREET 1: C/O GENENTECH INC STREET 2: 1 DNA WAY MS 49 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-4990 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENENTECH INC CENTRAL INDEX KEY: 0000318771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 942347624 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 DNA WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-225-1000 MAIL ADDRESS: STREET 1: 1 DNA WAY STREET 2: . CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgardoc.xml PRIMARY DOCUMENT X0201 4 2003-10-10 0 0000318771 GENENTECH INC DNA 0001214124 GARNICK ROBERT L 1 DNA WAY SO SAN FRANCISCO CA 94080 0 1 0 0 SENIOR VICE PRESIDENT Common Stock 2003-10-10 4 M 0 3794 41.8 A 3794 D Common Stock 2003-10-10 4 S 0 3794 81 D 0 D Common Stock 2003-10-10 4 M 0 18750 28.55 A 18750 D Common Stock 2003-10-10 4 S 0 18750 81 D 0 D Non-Qualified Stock Option (right to buy) 28.55 2003-10-10 4 M 0 18750 0 D 2002-09-12 2012-09-12 Common Stock 18750 56250 D Non-Qualified Stock Option (right to buy) 41.8 2003-10-10 4 M 0 3794 0 D 2001-09-26 2011-09-26 Common Stock 3794 30350 D This stock option vests over four years, with the first 25% of the shares vesting one year from the grant date and 75% of the shares vesting in equal monthly increments over the following three years. This option may be immediately exercisable with the consent of Genentech. Robert L. Garnick 2003-10-14 -----END PRIVACY-ENHANCED MESSAGE-----